[go: up one dir, main page]

CY1116646T1 - Αντικαρκινικη πρωτεϊνη συντηξης - Google Patents

Αντικαρκινικη πρωτεϊνη συντηξης

Info

Publication number
CY1116646T1
CY1116646T1 CY20151100743T CY151100743T CY1116646T1 CY 1116646 T1 CY1116646 T1 CY 1116646T1 CY 20151100743 T CY20151100743 T CY 20151100743T CY 151100743 T CY151100743 T CY 151100743T CY 1116646 T1 CY1116646 T1 CY 1116646T1
Authority
CY
Cyprus
Prior art keywords
fusion protein
sequence
region
terminus
cancer fusion
Prior art date
Application number
CY20151100743T
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Krzysztof Kazimierz Lemke
Sebastian Pawlak
Bartlomiej Zerek
Original Assignee
Adamed Sp. Z O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL393146A external-priority patent/PL393146A1/pl
Application filed by Adamed Sp. Z O.O. filed Critical Adamed Sp. Z O.O.
Publication of CY1116646T1 publication Critical patent/CY1116646T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Πρωτεΐνη σύντηξης η οποία αποτελείται από μία περιοχή (a) η οποία είναι λειτουργικό θραύσμα αλληλουχίας πρωτεΐνης hTRAIL, το οποίο θραύσμα ξεκινά με αμινοξύ σε θέση όχι χαμηλότερη από hTRAIL95, ή ομόλογο του εν λόγω λειτουργικού θραύσματος που έχει τουλάχιστον 70% ταυτότητα αλληλουχίας, και περιοχή (b) η οποία είναι αλληλουχία ανοσοδιεγερτικού πεπτιδίου τελεστή, όπου η αλληλουχία περιοχής (b) είναι προσαρτημένη στο C-άκρο ή Ν-άκρο της περιοχής (a). Η πρωτεΐνη σύντηξης μπορεί να χρησιμοποιηθεί για τη θεραπευτική αγωγή ασθενειών καρκίνου.
CY20151100743T 2010-12-03 2015-08-25 Αντικαρκινικη πρωτεϊνη συντηξης CY1116646T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL393146A PL393146A1 (pl) 2010-12-03 2010-12-03 Przeciwnowotworowe białko fuzyjne
PL39459711 2011-04-18
EP11790636.2A EP2646464B1 (en) 2010-12-03 2011-12-05 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
CY1116646T1 true CY1116646T1 (el) 2017-03-15

Family

ID=45065918

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100743T CY1116646T1 (el) 2010-12-03 2015-08-25 Αντικαρκινικη πρωτεϊνη συντηξης

Country Status (28)

Country Link
US (1) US9161991B2 (el)
EP (1) EP2646464B1 (el)
JP (1) JP5759557B2 (el)
KR (1) KR101952460B1 (el)
CN (1) CN103237808B (el)
AU (1) AU2011334868B2 (el)
BR (1) BR112013013548B8 (el)
CA (1) CA2814595C (el)
CY (1) CY1116646T1 (el)
DK (1) DK2646464T3 (el)
EA (1) EA024452B1 (el)
ES (1) ES2545895T3 (el)
HK (1) HK1186192A1 (el)
HR (1) HRP20150664T1 (el)
HU (1) HUE027068T2 (el)
IL (1) IL226207A (el)
ME (1) ME02224B (el)
MX (1) MX337436B (el)
NZ (1) NZ609216A (el)
PH (1) PH12013500714A1 (el)
PL (1) PL2646464T3 (el)
PT (1) PT2646464E (el)
RS (1) RS54057B1 (el)
SG (2) SG189370A1 (el)
SI (1) SI2646464T1 (el)
SM (1) SMT201500203B (el)
WO (1) WO2012072815A1 (el)
ZA (1) ZA201303449B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
US11136353B2 (en) 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
JP2023520922A (ja) 2020-04-10 2023-05-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構築物および関連組成物ならびに方法
WO2022197764A2 (en) 2021-03-16 2022-09-22 Cytomx Therapeutics, Inc. Masked activatable cytokine constructs and related compositions and methods
KR20230169700A (ko) 2022-06-09 2023-12-18 제주대학교 산학협력단 Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240068191A (ko) 2022-11-10 2024-05-17 제주대학교 산학협력단 리모닌을 유효성분으로 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240072614A (ko) 2022-11-17 2024-05-24 제주대학교 산학협력단 감귤 무봉 추출물을 유효성분으로 포함하는 탈모증상의 예방 개선 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
PT1666591E (pt) 1995-06-29 2011-06-01 Immunex Corp Citoquina que induz apoptose
EP1351709B8 (en) * 2000-06-09 2004-12-22 The Government of The United States of America, as represented by The Department of Health and Human Services Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
WO2002020715A2 (en) * 2000-09-05 2002-03-14 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
ATE501256T1 (de) 2003-11-03 2011-03-15 Beijing Sunbio Biotech Co Ltd Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
CN101365951B (zh) 2005-08-16 2013-09-11 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
ES2567704T3 (es) * 2007-07-10 2016-04-26 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
CA2697032C (en) * 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme

Also Published As

Publication number Publication date
KR101952460B1 (ko) 2019-02-27
MX337436B (es) 2016-03-03
US9161991B2 (en) 2015-10-20
SG189370A1 (en) 2013-05-31
BR112013013548A2 (pt) 2016-10-11
IL226207A0 (en) 2013-07-31
EP2646464B1 (en) 2015-06-03
HUE027068T2 (en) 2016-08-29
MX2013006213A (es) 2013-07-29
NZ609216A (en) 2014-05-30
BR112013013548B1 (pt) 2022-03-29
JP2014502158A (ja) 2014-01-30
IL226207A (en) 2016-07-31
US20130251676A1 (en) 2013-09-26
AU2011334868B2 (en) 2015-01-22
HK1186192A1 (en) 2014-03-07
PL2646464T3 (pl) 2015-10-30
ZA201303449B (en) 2014-01-29
SMT201500203B (it) 2015-10-30
KR20130122764A (ko) 2013-11-08
ES2545895T3 (es) 2015-09-16
ME02224B (me) 2016-02-20
EP2646464A1 (en) 2013-10-09
CN103237808A (zh) 2013-08-07
CA2814595C (en) 2020-06-16
RS54057B1 (en) 2015-10-30
PH12013500714A1 (en) 2013-06-10
SG10201509676UA (en) 2015-12-30
DK2646464T3 (en) 2015-08-24
AU2011334868A1 (en) 2013-05-02
JP5759557B2 (ja) 2015-08-05
EA201390820A1 (ru) 2013-12-30
HRP20150664T1 (hr) 2015-07-31
PT2646464E (pt) 2015-10-05
EA024452B1 (ru) 2016-09-30
SI2646464T1 (sl) 2015-07-31
CN103237808B (zh) 2016-02-24
BR112013013548B8 (pt) 2022-11-08
CA2814595A1 (en) 2012-06-07
WO2012072815A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1122178T1 (el) Πολυπεπτιδια
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
PH12014501083A1 (en) Anticancer fusion protein
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1122079T1 (el) Πρωτεϊνες επαναληψης διπεπτιδιου ως θεραπευτικος στοχος στις νευροεκφυλιστικες νοσους με επεκταση επαναληψης των εξανουκλεοτιδιων
CY1121953T1 (el) Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων
CY1121687T1 (el) Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
PL394618A1 (pl) Przeciwnowotworowe bialko fuzyjne
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
MX381726B (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
MX2020004271A (es) Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.
CY1121805T1 (el) Νουκλεϊνικο οξυ που περιλαμβανει ή κωδικοποιει στελεχος-βροχο ιστονης και πολυ(α) αλληλουχια ή σημα πολυαδενυλιωσης για αυξηση της εκφρασης ενος κωδικοποιημενου αντιγονου ογκου
MX2018002616A (es) Proteina de fusion.
BR112013011285A2 (pt) vacina